After attending Disc Medicine’s (IRON) analyst call in response to the media article that expressed concerns regarding CNPV program and mentioned potential timeline extension on the company’s Bitopertin/Erythropoietic Protoporphyria approval and skepticism on efficacy by FDA leader, Jefferies analyst Roger Song says that while the CNPV program’s timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin’s approval in EPP under CNPV, based on robust efficacy/safety, significant unmet needs, and to-date review experience. The firm sees today’s movement as a stock overreaction. Jefferies has a Buy rating on the shares with a price target of $154.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine (IRON): Constructive FDA Dialogue and APOLLO Progress Support Buy Rating Despite Volatility
- BMO Capital says call with Disc management clarifies active FDA dialogue
- TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact
- Disc Medicine falls -14.3%
- FDA voucher program allowing White House to intervene, STAT reports